Oncología

Resultados: 386
Tipo Título / Nombre Autor(es) Año
Manejo de síntomas generales Tejada Calvo P, Espacio Santos PM, Posada Restrepo A 2024
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer Torres-Esquius S, Llop-Guevara A, Gutiérrez-Enríquez S, Romey M..., Santiago González S 2024
Trombosis y cáncer Espacio Santos PM 2024
Preventing alpelisib-related hyperglycaemia in HR+/HER2?/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial Llombart Cussac A, Pérez García J, Ruiz Borrego M, Tolosa P..., González Santiago S 2024
Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data Cañueto J, Muñoz-Couselo E, Cardona-Machado C, Becerril-Andrés S, Martín-Vallejo J..., Ayala de Miguel P, et al 2024
Case-control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study García-Donas J, de Velasco G, Madurga R, Chamorro J, Rosero D..., Borrega P, et al 2024
Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast) Haba J de la, Anton A, Quiroga V..., Santiago González S 2023
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: Results from the observational study GEM1801. Ayala de Miguel P, Berciano Guerrero MA, Muñoz Couselo E, Manzano JL 2023
A phase 2 randomized pre-operative,window of opportunity trial investigating the effect of elacestrant with/without triptorelin in premenopausal patients with HR+/HER2- breast cancer – SOLTI-2104-PremiÈRe trial Bellet Ezquerra M, Hernando C, Tolosa P..., González Santiago S 2023
Lower pre-treatment B-cell gene expression signatures correspond with improved overall survival with palbociclib + endocrine therapy in HR+/HER2- metastatic breast cancer: a biomarker analysis from the GEICAM/2013-02 PEARL trial Agrawal Y, Fernández Martínez A, Gil Gil M..., González Santiago S 2023